Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSCAR: Adipose-derived Mesenchymal Stromal Cells for Kidney Transplant Rejection
NCT05456243Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2023
- Primary completion
- Apr 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic adipose-derived mesenchymal stromal cells in kidney transplant rejection (2 arms), sponsored by Mayo Clinic. Primary endpoints: Worsening kidney allograft rejection at 28 days and Adverse Events at 1 year. Started Jan 2023; status: completed.
02
Drugs
allogeneic adipose-derived mesenchymal stromal cells
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05456243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456243.